// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,878
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,878 results Live
Leadership NEED Jun 3 ▲ +0.50

New ERA Energy appoints Darin Rovell as Chief Accounting Officer

New ERA Energy & Digital, Inc. entered into an employment agreement with Darin Rovell effective June 22, 2026, appointing him as Chief Accounting Officer at an annual base salary o…

Offering ASTRO Jun 3 — 0.00

Astrotech Corp enters at-the-market offering agreement with H.C. Wainwright

Astrotech Corporation has entered into an ATM offering agreement with H.C. Wainwright & Co., LLC dated June 2, 2026, allowing the company to sell shares opportunistically. This pro…

Other UPBD Jun 3 — 0.00

Upbound Group amends 2026 long-term incentive plan, increasing share limit to 4.59M

Upbound Group increased the aggregate share authorization under its 2026 Long-Term Incentive Plan to 4,590,636 shares of common stock as of June 2, 2026. The amendment allows the c…

Offering LUNR Jun 3 — -0.10

Intuitive Machines establishes $500M at-the-market offering agreement

Intuitive Machines entered into a sales agreement with 10 financial institutions to sell up to $500 million of Class A common stock through an at-the-market offering. The offering …

Leadership GEN Jun 3 ▲ +0.50

GEN Restaurant Group hires Luke Hewko as Chief Financial Officer

GEN Restaurant Group has appointed Luke Hewko as Chief Financial Officer effective June 1, 2026, with an annual salary of $300,000. The appointment adds senior financial leadership…

FDA Somerset Jun 3 — 0.00

FDA Approves TOFACITINIB — Somerset Therapeutics, LLC

# FDA Approves Generic Tofacitinib; Somerset Therapeutics Enters Competitive JAK Inhibitor Market Somerset Therapeutics, LLC has received FDA approval for its generic tofacitinib …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

# FDA Approves Generic Tofacitinib from Novadoz Pharmaceuticals Novadoz Pharmaceuticals LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking…

FDA Sun Jun 3 — 0.00

FDA Approves TOFACITINIB — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries has received FDA approval for its generic tofacitinib citrate oral formulation, a regulatory milestone expected to drive revenue growth as the company…

FDA Breckenridge Jun 3 — 0.00

FDA Approves TOFACITINIB — Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical’s FDA approval for oral tofacitinib citrate is set to introduce aggressive competition to the branded market, likely pressuring the sole brand-name entr…

FDA Aurobindo Jun 3 — 0.00

FDA Approves TOFACITINIB — Aurobindo Pharma Limited

Aurobindo Pharma received FDA approval for its generic tofacitinib citrate oral tablets on June 3, 2026, establishing a new entrant in the JAK inhibitor market. This authorization …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals secured FDA approval June 3, 2026, for oral Tofacitinib Citrate tablets, positioning the firm to capitalize on a significant rheumatoid arthritis market. Th…

FDA SPECGX Jun 3 — 0.00

FDA Approves Unknown Drug — SPECGX LLC

SpecGx LLC has received FDA approval for ANDA 219395, signaling an imminent opportunity for the company to enter the market with the companion diagnostic product. This regulatory m…

FDA Apotex Jun 3 — 0.00

FDA Approves TOFACITINIB — Apotex Corp.

Apotex has secured FDA approval for the generic version of tofacitinib (ANDA218096), slated for release on June 3, 2026, which is set to intensify commercial competition and exert …

Offering BRIA Jun 3 — 0.00

BriaCell issues placement agent warrants exercisable from June 2026

BriaCell Therapeutics filed a warrant agreement allowing placement agents to purchase common shares starting June 2, 2026, expiring five years later per FINRA rules. The warrant is…

Offering DORM Jun 3 — +0.10

Dorman Products announces $450M senior notes offering due 2034

Dorman Products commenced a private offering of $450 million in senior notes due 2034 to qualified institutional buyers, with proceeds designated for debt repayment and general cor…

Restructuring HLLK Jun 3 ▼ -0.60

Hallmark Venture assigns $113.8K impaired debt note from Traderverse Inc.

Hallmark Venture Group assigned its promissory note from Traderverse Inc., which had a December 2025 balance of approximately $113,752 and was already written down as impaired, to …

Other NAUT Jun 2 — 0.00

Nauticus Robotics amends loan agreement with third amendment to existing terms

Nauticus Robotics executed a third amendment to its loan agreement, modifying lender obligations and stockholder voting rights capped at 4.99% ownership. The amendment clarifies le…

Buyback NWS Jun 2 ▲ +0.50

News Corp initiates $1 billion share repurchase program for Class A stock

News Corporation announced a buyback program authorizing repurchase of up to $1 billion in aggregate of the company's Class A common stock. The share repurchase reflects management…

Leadership SKY Jun 2 ▲ +0.60

Champion Homes appoints three executives following Kimmell retirement

Champion Homes announced leadership appointments of Wade Lyall as Chief Sales Officer, John Kastanek as Chief Customer Experience Officer, and Andrew Houser as Senior Vice Presiden…

Offering NUO Jun 2 — +0.10

Nuo Therapeutics issues common stock purchase warrants with $1.50 exercise price.

Nuo Therapeutics issued interim common stock purchase warrants dated May 29, 2026, exercisable through January 23, 2031, in connection with a Loan and Security Agreement. The warra…